# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Chardan Capital analyst Daniil Gataulin initiates coverage on Cognition Therapeutics (NASDAQ:CGTX) with a Buy rating and ann...
HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on Cognition Therapeutics (NASDAQ:CGTX) with a Buy rat...
B. Riley Securities analyst Mayank Mamtani reiterates Cognition Therapeutics (NASDAQ:CGTX) with a Buy and maintains $5 price...
Oppenheimer analyst Jay Olson maintains Cognition Therapeutics (NASDAQ:CGTX) with a Outperform and maintains $9 price target.
Cognition Therapeutics (NASDAQ:CGTX) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate o...